Literature DB >> 25963852

Childhood cancers in families with and without Lynch syndrome.

John A Heath1,2, Jeanette C Reece1, Daniel D Buchanan1,3, Graham Casey4, Carol A Durno5,6,7, Steven Gallinger8, Robert W Haile9, Polly A Newcomb10,11, John D Potter10,11,12, Stephen N Thibodeau13, Loïc Le Marchand14, Noralane M Lindor15, John L Hopper1,16,17, Mark A Jenkins1, Aung Ko Win18.   

Abstract

Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes or the EPCAM gene is associated with an increased risk of colorectal cancer, endometrial cancer, and other adult malignancies (Lynch syndrome). The risk of childhood cancers in Lynch syndrome families, however, is not well studied. Using data from the Colon Cancer Family Registry, we compared the proportion of childhood cancers (diagnosed before 18 years of age) in the first-, second-, and third-degree relatives of 781 probands with a pathogenic mutation in one of the MMR genes; MLH1 (n = 275), MSH2 (n = 342), MSH6 (n = 99), or PMS2 (n = 55) or in EPCAM (n = 10) (Lynch syndrome families), with that of 5073 probands with MMR-deficient colorectal cancer (non-Lynch syndrome families). There was no evidence of a difference in the proportion of relatives with a childhood cancer between Lynch syndrome families (41/17,230; 0.24%) and non-Lynch syndrome families (179/94,302; 0.19%; p = 0.19). Incidence rate of all childhood cancers was estimated to be 147 (95% CI 107-206) per million population per year in Lynch syndrome families and 115 (95% CI 99.1-134) per million population per year in non-Lynch syndrome families. There was no evidence for a significant increase in the risk of all childhood cancers, hematologic cancers, brain and central nervous system cancers, Lynch syndrome-associated cancers, or other cancers in Lynch syndrome families compared with non-Lynch syndrome families. Larger studies, however, are required to more accurately define the risk of specific individual childhood cancers in Lynch syndrome families.

Entities:  

Keywords:  Childhood cancer; Familial cancer; Lynch syndrome; Mismatch repair

Mesh:

Substances:

Year:  2015        PMID: 25963852      PMCID: PMC4631656          DOI: 10.1007/s10689-015-9810-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  25 in total

1.  Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

Authors:  R C Niessen; M J W Berends; Y Wu; R H Sijmons; H Hollema; M J L Ligtenberg; H E K de Walle; E G E de Vries; A Karrenbeld; C H C M Buys; A G J van der Zee; R M W Hofstra; J H Kleibeuker
Journal:  Gut       Date:  2006-04-24       Impact factor: 23.059

Review 2.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.

Authors:  Noralane M Lindor; Gloria M Petersen; Donald W Hadley; Anita Y Kinney; Susan Miesfeldt; Karen H Lu; Patrick Lynch; Wylie Burke; Nancy Press
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

3.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

4.  Population-based survival estimates for childhood cancer in Australia during the period 1997-2006.

Authors:  P D Baade; D R Youlden; P C Valery; T Hassall; L Ward; A C Green; J F Aitken
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

5.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.

Authors:  Marjolijn J L Ligtenberg; Roland P Kuiper; Tsun Leung Chan; Monique Goossens; Konnie M Hebeda; Marsha Voorendt; Tracy Y H Lee; Danielle Bodmer; Eveline Hoenselaar; Sandra J B Hendriks-Cornelissen; Wai Yin Tsui; Chi Kwan Kong; Han G Brunner; Ad Geurts van Kessel; Siu Tsan Yuen; J Han J M van Krieken; Suet Yi Leung; Nicoline Hoogerbrugge
Journal:  Nat Genet       Date:  2008-12-21       Impact factor: 38.330

6.  Trends in childhood cancer incidence in the U.S. (1992-2004).

Authors:  Amy M Linabery; Julie A Ross
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

7.  Time trends and characteristics of childhood cancer among children age 0-14 in Shanghai.

Authors:  Ping-Ping Bao; Ying Zheng; Chun-Fang Wang; Kai Gu; Fan Jin; Wei Lu
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

8.  Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.

Authors:  Susanne Magnusson; Ake Borg; Ulf Kristoffersson; Mef Nilbert; Thomas Wiebe; Håkan Olsson
Journal:  Fam Cancer       Date:  2008-05-15       Impact factor: 2.375

9.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.

Authors:  Leigha Senter; Mark Clendenning; Kaisa Sotamaa; Heather Hampel; Jane Green; John D Potter; Annika Lindblom; Kristina Lagerstedt; Stephen N Thibodeau; Noralane M Lindor; Joanne Young; Ingrid Winship; James G Dowty; Darren M White; John L Hopper; Laura Baglietto; Mark A Jenkins; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2008-05-02       Impact factor: 22.682

10.  Lynch syndrome in a 15-year-old boy.

Authors:  A Bodas; P Pérez-Segura; C Maluenda; T Caldés; E Olivera; E Díaz-Rubio
Journal:  Eur J Pediatr       Date:  2008-01-04       Impact factor: 3.183

View more
  1 in total

1.  High Prevalence of Alterations in DNA Mismatch Repair Genes of Lynch Syndrome in Pediatric Patients with Adrenocortical Tumors Carrying a Germline Mutation on TP53.

Authors:  Vania Balderrama Brondani; Luciana Montenegro; Amanda Meneses Ferreira Lacombe; Breno Marchiori Magalhães; Mirian Yumie Nishi; Mariana Ferreira de Assis Funari; Amanda de Moraes Narcizo; Lais Cavalca Cardoso; Sheila Aparecida Coelho Siqueira; Maria Claudia Nogueira Zerbini; Francisco Tibor Denes; Ana Claudia Latronico; Berenice Bilharinho Mendonca; Madson Queiroz Almeida; Antonio Marcondes Lerario; Ibere Cauduro Soares; Maria Candida Barisson Villares Fragoso
Journal:  Cancers (Basel)       Date:  2020-03-07       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.